參考文獻
黃毓惠、謝祖怡、蔡呈芳、王鼎舜、蘇維鈞、陳得源•(2016)•生物製劑治療期間定期監測結核病發生風險之必要性: 台灣專家之臨床經驗與建議•Formosan Journal of Rheumatology, 30(2), 33-40.
Chiu, H. Y., Wang, T. S., Chen, P. H., Hsu, S. H., Tsai, Y. C., & Tsai, T. F. (2018). Psoriasis in Taiwan: From epidemiology to new treatments. Dermatologica Sinica, 36(3), 115-123.
Nestle F.O., Kaplan D.H., Barker J. (2009). Psoriasis. New England Journal of Medicine, 361, 496-509.
Tausend, W., Downing, C., & Tyring, S. (2014). Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. Journal of cutaneous medicine and surgery, 18(3), 156-169.